Thyroid Cancer Trial, Recruiting NCT07270237 Sponsor: Memorial Sloan Kettering Cancer Center Condition: Thyroid Cancer
Back to Thyroid Cancer

Thyroid Cancer Trial, Recruiting

NCT07270237
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

This trial has several different groups (cohorts). You may qualify for one of the following:

Group 1 – People at high risk for pancreatic cancer (having a routine surveillance ultrasound):

  • You are already enrolled in the Memorial Sloan Kettering Pancreatic Registry program
  • You do not have pancreatic cancer yourself, but have a family history that puts you at higher risk
  • You are at least 10 years younger than the youngest family member diagnosed with pancreatic cancer
  • You are at least 50 years old (general requirement), OR at least 40 years old if you have been diagnosed with FAMMM syndrome or Hereditary Pancreatitis, OR at least 35 years old if you have been diagnosed with Peutz-Jeghers syndrome
  • You are not pregnant and not breastfeeding
  • You agree to be contacted for follow-up
  • You meet at least one of these four family/genetic conditions:
    • You have at least two relatives who had pancreatic cancer, where at least one is closely related to each other and at least one is a close (first-degree) relative of yours; OR you have at least two close (first-degree) relatives on the same side of the family with pancreatic cancer
    • You have at least one close or moderately close relative with pancreatic cancer AND genetic testing has found a significant gene change in one of several specific genes (such as BRCA1, APC, MLH1, MSH2, MSH6, PMS2, EPCAM, PALB2, TP53, or others at the trial team's discretion)
    • Genetic testing has found a significant gene change in one of several other specific genes linked to cancer risk (such as CDKN2A/p16, STK11, PRSS1, SPINK1, CTRC, CPA1, ATM, BRCA2, or others at the trial team's discretion)
    • You are a relative aged 21 or older with other high-risk factors that the lead doctor determines warrant pancreatic cancer monitoring (confirm with trial site)

Group 2 – People diagnosed with pancreatic cancer:

  • You have been diagnosed with a specific type of pancreatic cancer called pancreatic ductal adenocarcinoma
  • You are already scheduled to have an ultrasound-guided biopsy of your pancreas as part of your normal care
  • You are not pregnant and not breastfeeding

Group 3 – People with a thyroid nodule:

  • You have a thyroid nodule and are already scheduled to have an ultrasound-guided biopsy of it as part of your normal care (you may or may not have a known cancer diagnosis)
  • You are not pregnant and not breastfeeding

Healthy Volunteers:

  • You have no known cancer diagnosis and no known thyroid nodules
  • You are 18 years of age or older
  • You are able to understand and sign a consent form
  • You are not pregnant and not breastfeeding

Who may not be able to join:

  • You are unable to sign a consent form for medical or any other reason
  • You live outside the continental United States
  • You are under 18 years of age (applies to Groups 2 and 3)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Mark T Burgess, MD, Memorial Sloan Kettering Cancer Center

Phone: 646-608-8284

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
24 November 2025
Est. completion
1 November 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

investigate the feasibility of mpEUS imaging

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov